摘要：2025年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会（ASCO GU）将于2月13日至15日在加利福尼亚州旧金山召开，旨在向全球肿瘤学者传递国际泌尿肿瘤领域的最新研究进展。目前，大会官网已披露了摘要标题，医脉通特此整理相关摘要，希望与广大读者共同预瞻那些即将在国际
前言
2025年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会（ASCO GU）将于2月13日至15日在加利福尼亚州旧金山召开，旨在向全球肿瘤学者传递国际泌尿肿瘤领域的最新研究进展。目前，大会官网已披露了摘要标题，医脉通特此整理相关摘要，希望与广大读者共同预瞻那些即将在国际舞台上奏响的中国强音。
Oral Abstract Session
01 摘要号：665
Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial
维迪西妥单抗联合特瑞普利单抗新辅助治疗HER2表达的肌层浸润性膀胱癌（MIBC）患者：II 期 RC48-C017 试验的最新疗效和安全性结果
讲者：盛锡楠 北京大学肿瘤医院
General Session
01 摘要号：657
Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study
Nectin-4 靶向 ADC，SHR-A2102，用于治疗晚期或转移性尿路上皮癌患者：一项 1 期研究
讲者：唐碧霞 北京大学肿瘤医院
Rapid Oral Abstract Session
01 摘要号：443
Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study
仑伐替尼联合替雷利珠单抗作为晚期富马酸水合酶缺陷型肾细胞癌的一线治疗：一项单中心、单臂、II 期研究
讲者：孔文 上海交通大学医学院附属仁济医院
Poster Session
前列腺癌
01 摘要号：47
The comparison of clinical utility between pan-cancer panel and PCa-specific panel for mCRPC
讲者：董柏君 上海交通大学医学院附属仁济医院
02 摘要号：78
The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer
讲者：Qian Wang 四川大学华西医院
03 摘要号：103
Clinical features and prognostic value of CDK12 mutation in prostate cancer patients
讲者：董柏君 上海交通大学医学院附属仁济医院
04 摘要号：161
Updated results from a phase I/II study of CBP-1018, a bi-ligand–drug conjugate (Bi-XDC) as late line therapy for patients with metastatic castration resistant prostate cancer (mCRPC)
讲者：李锴文 中山大学孙逸仙纪念医院
05 摘要号：214
The prognostic significance of circulating tumor DNA in prostate cancer: A systematic review and meta-analysis
讲者：Haolin Liu 四川大学华西医院
06 摘要号：325
Global spatiotemporal trends in prostate cancer burden and its socioeconomic disparities: An observational study from 1990 to 2021
讲者：Xianghong Zhou 四川大学华西医院
07 摘要号：328
An online clustering algorithm predicting model for prostate cancer based on PHI-related variables and PI-RADS in different PSA populations
讲者：张阁钧 中国医科大学第一附属医院
08 摘要号：333
Interpretable machine learning for prostate biopsy: Cohort study
讲者：Jindong Dai 四川大学华西医院
09 摘要号：340
Optimizing the strategies to perform prostate biopsy in MRI-positive patients: A systematic review and network meta-analysis
讲者：Qiyou Wu 四川大学华西医院
10 摘要号：390
Evaluating the efficacy and safety of pelvic lymph node dissection in high-risk prostate cancer patients undergoing radical prostatectomy: A systematic review and meta-analysis
讲者：Qihao Wang 四川大学华西医院
11 摘要号：404
Phenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: Results from a large-scale longitudinal cohort study
讲者：Xiaoyang Liu 四川大学华西医院
12 摘要号：406
Chimeric RNA landscape in the Chinese population and the role of SFT2D2-TBX19 in prostate cancer progression
讲者：Qiong Wang 南方医科大学南方医院
13 摘要号：411
The impact of neoadjuvant therapy on the formation of tertiary lymphatic structures and the distinct prognosis in prostate cancer
讲者：Yunfei Yu 四川大学华西医院
14 摘要号：423
Assessment of the proficiency of ChatGPT-4o in an image-based robot-assisted radical prostatectomy scenario
讲者：Jiakun Li 四川大学华西医院
15 摘要号：TPS278
Efficacy and safety of organoid-based drug sensitivity screening to guide the treatment of mCRPC patients progressed after first-line treatment
讲者：Diwei Zhao 中山大学肿瘤防治中心
16 摘要号：TPS292
A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in metastatic hormone sensitive prostate cancer patients with HRR gene mutation: Updated analysis of PROact
讲者：邱雪峰 南京鼓楼医院
17 摘要号：TPS299
Tislelizumab in combination with abiraterone/enzalutamide for metastatic castration-resistant prostate cancer with intraductal adenocarcinoma of the prostate after progression on prior androgen receptor pathway inhibitor
讲者：Qiyu Zhu 四川大学华西医院
18 摘要号：TPS307
Circulating tumor DNA (ctDNA) monitoring in the assessment and prediction of the efficacy of PARP inhibitors (PARPi)
讲者：Diwei Zhao 中山大学肿瘤防治中心
尿路上皮癌
01 摘要号：673
Postoperative adjuvant treatment of HER2 overexpression in upper urinary tract urothelial carcinoma with the combination of disitamab vedotin and toripalimab: A real-world retrospective study
讲者：张顺 南京鼓楼医院
02 摘要号：688
Predictive value of neoadjuvant therapy combined with VI-RADS re-scoring in bladder preservation for muscle-invasive bladder cancer
讲者：袁方 重庆大学肿瘤医院
03 摘要号：703
Intravesical gemcitabine and docetaxel combined with intravenous tislelizumab as a durable strategy for high-risk non–muscle-invasive bladder cancer
讲者：xiaobao chen 福建医科大学附属协和医院
04 摘要号：710
Effectiveness and safety of RC48-ADC in combination with toripalimab as neoadjuvant treatment in HER2-positive muscular invasive urothelial bladder cancer patients
讲者：李成龙 武汉大学人民医院
05 摘要号：713
First-line therapies analysis in advanced/metastatic urothelial carcinoma: Prognostic insights with propensity score analysis and RNA-seq
讲者：王晶晶 中南大学湘雅二医院
06 摘要号：721
Modified transurethral resection of bladder tumors: A comparison study of chemotherapy-enhanced endoscopic submucosal en bloc dissection versus conventional resection
讲者：Xi Liu 辽宁省肿瘤医院
07 摘要号：726
Efficacy and safety of disitamab vedotin combined with toripalimab as neoadjuvant treatment for patients with locally advanced muscle-invasive bladder cancer: A mono-institutional retrospective study
讲者：Geng Zhang 第四军医大学西京医院
08 摘要号：729
Survival impact of concomitant squamous differentiation in upper tract urothelial carcinoma patients receiving adjuvant chemotherapy
讲者：Jianjun Ye 四川大学华西医院
09 摘要号：733
A retrospective real-world study of disitamab vedotin combined with tislelizumab versus chemotherapy in patients with previously untreated metastatic urothelial carcinoma
讲者：Han Se 包头医学院
10 摘要号：763
Phase Ib/II clinical trial of oncolytic virus intravesical irrigation for preventing recurrence after TURBT in patients with recurrent high-risk NMIBC
讲者：关有彦 中国医学科学院肿瘤医院
11 摘要号：767
PUNCH01: Interim results from a phase II study of intra‑arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC)
讲者：王宗任 中山大学附属第一医院
12 摘要号：772
Impact of adjuvant intraarterial chemotherapy on survival for patients with stage IIIA-IIIB bladder urothelial carcinoma after radical cystectomy: An open-label, prospective, randomized clinical trial
讲者：Zhaohui Zhou 中山大学肿瘤防治中心
13 摘要号：775
Preliminary efficacy and safety of disitamab vedotin (DV) combined with bacillus Calmette-Guérin (BCG) in the treatment of high-risk non-muscle invasive bladder cancer with HER2 expression: A prospective, open label, single-center study
讲者：沈益君 复旦大学附属肿瘤医院
14 摘要号：784
Efficacy and safety of tislelizumab (T) combined with gemcitabine and cisplatin (GC) for patients with localized muscle-invasive bladder cancer (MIBC) after radical transurethral resection of bladder tumor/partial cystectomy: A prospective, phase II study
讲者：曹明 上海交通大学医学院附属仁济医院
15 摘要号：786
Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02)
讲者：沈亚丽 四川大学华西医院
16 摘要号：787
Safety and efficacy of intravesical bacillus Calmette-Guerin instillation for superficial recurrence following bladder-sparing therapy of muscle invasive bladder cancer
讲者：Gan Du 中国医学科学院肿瘤医院
17 摘要号：789
Efficacy and safety of fexagratinib (Fexa) in combination with tislelizumab (T) in a phase II study of patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) harboring FGFR alterations (FGFRa)
讲者：卞晓洁 复旦大学附属肿瘤医院
18 摘要号：790
Efficacy and safety of fexagratinib (Fexa) in Chinese patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) harboring FGF receptor (FGFR) genetic alterations
讲者：卞晓洁 复旦大学附属肿瘤医院
19 摘要号：791
Kidney-sparing approach for selected localized high-risk upper tract urothelial carcinoma: A pilot study combining endoscopic thulium laser ablation with perioperative disitamab vedotin and immune checkpoint inhibitors
讲者：Jianjun Ye 四川大学华西医院
20 摘要号：794
Comprehensive modalities of kidney-sparing treatment in a carefully selected cohort of localized high-risk upper tract urothelial carcinoma: A potential paradigm shift
讲者：Zeyu Chen 四川大学华西医院
21 摘要号：795
A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03)
讲者：张朋 四川大学华西医院
22 摘要号：796
Efficacy and safety of sacituzumab tirumotecan monotherapy in patients with advanced urothelial carcinoma who progressed on or after prior anti-cancer therapies: Report from the phase 1/2 MK-2870-001 study
讲者：叶定伟 复旦大学附属肿瘤医院
23 摘要号：805
Safety and efficacy of bladder preservation therapy for very high-risk non-muscle-invasive bladder cancer: A single-center, single-arm prospective study (CIP-1)
讲者：袁方 重庆大学肿瘤医院
24 摘要号：812
Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study
讲者：毕新刚 中国医学科学院肿瘤医院
25 摘要号：829
Comprehensive investigation of CPSF3's role in the progression of bladder cancer
讲者：Zhiyang Ma 上海交通大学医学院附属瑞金医院
26 摘要号：837
Changes in circulating tumor cells (CTCs) and HER2 expression in evaluating the efficacy of neoadjuvant disitamab vedotin plus toripalimab treatment in patients with muscle-invasive bladder cancer (MIBC)
讲者：曹煜东 北京大学肿瘤医院
27 摘要号：839
Discordance in HER2 expression in primary and recurrent/metastatic lesions of upper tract urothelial carcinoma: A study focusing on temporal heterogeneity
讲者：Jianjun Ye 四川大学华西医院
28 摘要号：841
Pathological subclassification of T3 upper tract urothelial carcinoma: Complementary evidence for existing guidelines
讲者：Lei Zheng 四川大学华西医院
29 摘要号：844
Use of urinary cell-free DNA methylation assay to identify tumor fraction for early detection and recurrence monitoring in urothelial carcinoma
讲者：赵焕 中国医学科学院肿瘤医院
30 摘要号：846
Use of urinary cell-free DNA fragmentomics in urothelial carcinoma diagnosis
讲者：赵焕 中国医学科学院肿瘤医院
31 摘要号：852
Protein analysis of urachal carcinoma tissue based on different antibody-drug conjugate therapeutic targets
讲者：Tian Han 中国医学科学院肿瘤医院
32 摘要号：854
Impact of loss of PRLHR on aneuploidy and initiation of bladder cancer
讲者：Xi Zheng南京鼓楼医院
33 摘要号：868
A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy
讲者：JINCHANG WEI 北京大学肿瘤医院
34 摘要号：TPS894
Formula-01: A phase Ⅱ study of disitamab vedotin (RC48) intravenous injection combined with BCG intravesical instillation in high-risk non-muscle invasive bladder cancer with HER2 high expression
讲者：谭星亮 中山大学肿瘤防治中心
35 摘要号：TPS895
A clinical trial evaluating the efficacy and safety of disitamab vedotin plus tislelizumab combined with re-TURBT in the treatment of HER-2-high expression (2+-3+) non-muscle invasive bladder cancer at high-risk and very high-risk
讲者：陈剑晖 福建医科大学附属协和医院
肾细胞癌、阴茎癌、睾丸癌和尿道癌
01 摘要号：6
Risk factors of complications after inguinal lymph node dissection in patients with penile cancer
讲者：Yilong Gao 四川大学华西医院
02 摘要号：8
Apatinib monotherapy for pretreated advanced squamous cell carcinoma of the penis: A phase II trial
讲者：张盛 复旦大学附属肿瘤医院
03 摘要号：481
Observational study of tislelizumab (Tisle) combined with pazopanib in reducing venous tumor thrombus in clear cell renal cell carcinoma with venous invasion
讲者：拜合提亚尔·艾合买提江 新疆医科大学第一附属医院
04 摘要号：500
Safety and efficacy of immune checkpoint inhibitor rechallenge in metastatic fumarate hydratase-deficient renal cell carcinoma: A retrospective study
讲者：Yanfeng Tang 四川大学华西医院
05 摘要号：504
Clinicopathological characteristics and prognosis of metastatic non-clear cell renal cell carcinoma
讲者：Jie Wu 浙江省肿瘤医院
06 摘要号：529
Efficacy and safety of SABR with TKI and IO therapy in patients with mRCC
讲者：杨恺惟 北京大学第一医院
07 摘要号：530
Cadonilimab combined with lenvatinib for neoadjuvant therapy in early-stage renal cell carcinoma with indications for partial nephrectomy but high surgical risk: A prospective single-arm phase II clinical trial
讲者：彭毓璐 中山大学肿瘤防治中心
08 摘要号：532
Efficacy of selective renal tumor embolization combined with axitinib and reduced-dose toripalimab in oligometastatic clear cell renal carcinoma: A comparative analysis with axitinib combined with standard-dose toripalimab
讲者：杜君 天津医科大学肿瘤医院
09 摘要号：534
Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease–associated tumors: Results of LITESPARK-015 study
讲者：龚侃 北京大学第一医院
10 摘要号：542
Efficacy and safety of fruquintinib combined with serplulimab as 1st line treatment in metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC): Updated results from a single-arm, multicentre clinical trial
讲者：黄吉炜 上海交通大学医学院附属仁济医院
11 摘要号：544
Cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) combined with axitinib for the first-line treatment of advanced or metastatic non-clear renal cell carcinoma: A prospective, single-arm, phase Ib/II study
讲者：胡旭 四川大学华西医院
12 摘要号：550
Efficacy of systemic treatments for advanced non-clear cell renal cell carcinoma: A single-arm systematic review and meta-analysis
讲者：Xinyuan Wei 四川大学华西医院
13 摘要号：556
The evaluation of therapeutic outcomes of percutaneous US/CT-guided bipolar radiofrequency ablation for small renal masses under local anesthesia
讲者：Yifan Sun 南京鼓楼医院
14 摘要号：557
A phase II clinical study of camrelizumab plus apatinib in combination with stereotactic body radiotherapy (SBRT) for advanced non-clear cell renal cell carcinoma (nccRCC)
讲者：Xinyue Zhang 中山大学肿瘤防治中心
15 摘要号：563
Prognostic value of preoperative fibrinogen in metastatic clear cell renal cell carcinoma patients undergoing cytoreductive nephrectomy: A propensity score-matched study
讲者：寿建忠 中国医学科学院肿瘤医院
16 摘要号：585
Use of integrated multi-omics analysis to analyze prognostic molecular subtype in collecting duct carcinoma
讲者：Xiaowen Wu 北京大学肿瘤医院
A prospective, single-center, single-arm clinical study of adjuvant toripalimab combined with axitinib in non-clear renal cell carcinoma (nccRCC) patients with high-risk recurrence factors (IUNU-RC-102)
讲者：刘光香 南京鼓楼医院
VORSIN-RCC: Vorolanib plus sintilimab for advanced renal cell carcinoma after failure of prior immune checkpoint inhibitors-based combination therapy
讲者：Yu Shen 四川大学华西医院
编辑：Lya/Faline
审校：Faline
排版：Faline
执行：Aurora
医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。
本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。
来源：医脉通肿瘤科
